From 1 July, the NIP Schedule at 12 months of age is changing 1-4
To ensure the NIP Schedule is aligned with changes in disease patterns, an update has been made to the recommendations on the use of pneumococcal and meningococcal vaccines.2,3
There has been a change of schedule for pneumococcal conjugate vaccination, where for all children without increased risk of pneumococcal disease the 6-month dose of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed) has been moved to 12 months.1,2,4
All children who have previously received Prevenar 13 at 2, 4 and 6 months should receive one dose at 12 months.1,2,4
Since the introduction of Prevenar 13, there has been a large reduction in vaccine-type invasive pneumococcal disease (IPD) cases. In recent years, there has been an increase in the number of cases of IPD seen in children beyond 12 months of age.2
Aboriginal and Torres Strait Islander children in WA, NT, SA, and QLD, and all children with underlying medical conditions associated with an increased risk of invasive pneumococcal disease, should receive Prevenar 13 at 2, 4, 6 and 12 months (3+1 schedule).2
Meningococcal quadrivalent vaccination is new to the schedule, where for all children the 12-month dose of HibMenC vaccine has been replaced by Nimenrix (meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine).1,3,4 The fourth dose of Hib vaccine has been moved to 18 months.1 There is no change to the MMR vaccine.1
|From 1 July, at 12 months of age, every child needs 3 injections|
|An injection for pneumococcal disease||Prevenar 13||Change of schedule1,2,4|
|An injection for invasive meningococcal disease (A,C,W-135,Y)||Nimenrix||New to schedule1,3,4|
|A combined injection for measles, mumps, rubella||MMR||No change1|
Parents can be assured that each of the three vaccines in the updated NIP Schedule is important and can be administered concurrently.1–6
The following video contains tips and techniques for delivering multiple injections, as well as advice on how to reassure parents who may be concerned about concurrent administration of vaccines.
|Resources to help you with this change|
|National Immunisation Program Schedule||Immunise.health.gov.au|
|National Immunisation Hotline||1800 671 811|
|Department of Health Resources link||https://bit.ly/2tUwMaY|
|National Centre for Immunisation Research & Surveillance fact sheets||ncirs.edu.au/provider-resources/ncirs-fact-sheets|
|Multiple Injection Technique video||https://goo.gl/bh59K7|
|Pfizer Medical Information||1800 675 229|
|Prevenar 13 and Nimenrix Product Information||pfizer.com.au|
|State Health Services||Contact your State Department of Health for more info.|
There is no catch-up program available. Prevenar 13 and Nimenrix remain available on private prescription for patient’s ineligible via the NIP.
NIP: National Immunisation Program; HibMenC: Haemophilus influenzae type b and Meningococcal C vaccine; Hib: Haemophilus influenzae type b; MMR: measles, mumps and rubella virus vaccine.
This content has been produced by Pfizer.
- Australian Government Department of Health. National Immunisation Program Schedule. Available at: https://bit.ly/2EkXr3I (accessed: August 2018).
- Australian Government Department of Health: Australian Technical Advisory Group on Immunisation. Public consultation on the infant pneumococcal vaccination schedule. Available at: https://bit.ly/2IcQ9WF (accessed: August 2018).
- Australian Government Department of Health: Australian Technical Advisory Group on Immunisation. Public consultation on changes to the recommended use of meningococcal and Haemophilus influenzae type B vaccines. Available at: https://bit.ly/2Gf9cd7 (accessed: August 2018).
- Australian Government Department of Health: Australian Technical Advisory Group on Immunisation (ATAGI) advice to support changes to the National Immunisation Program from 1 July 2018. Available at:https://bit.ly/2IcQ9WF (accessed: August 2018)
- Prevenar 13® Approved Product Information.
- Nimenrix™ Approved Product Information.
TM Trademark,®Registered trademark. Pfizer Australia Pty Limited, Sydney, Australia. PP-PNP-AUS-0089